Advances and controversies in management of breast ductal carcinoma in situ (DCIS).
Farante G, Toesca A, Magnoni F, Lissidini G, Vila J, Mastropasqua M, Viale G, Penco S, Cassano E, Lazzeroni M, Bonanni B, Leonardi MC, Ripoll-Orts F, Curigliano G, Orecchia R, Galimberti V, Veronesi P.
Farante G, et al.
Eur J Surg Oncol. 2022 Apr;48(4):736-741. doi: 10.1016/j.ejso.2021.10.030. Epub 2021 Nov 9.
Eur J Surg Oncol. 2022.
PMID: 34772587
Review.
Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. It accounts for 25% of all breast cancers diagnosed, as a result of the expansion of breast cancer screening and is associated with a high survival rate. ...
Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. It accounts for 25% of all breast …